Palliative systemic therapy for women with recurrent epithelial ovarian cancer: current options

References

• Canadian Cancer Society’s Steering Committee on Cancer StatisticsCanadian Cancer Statistics 2012Toronto, ONCanadian Cancer Society2012 Available from: http://www.cancer.ca/Canada-wide/About%20cancer/~/media/CCS/Canada%20wide/Files%20List/English%20files%20heading/PDF%20-%20Policy%20-%20Canadian%20Cancer%20Statistics%20-%20English/Canadian%20Cancer%20Statistics%202012%20-%20English.ashxAccessed September 15, 2012
   Google Scholar
• FlemingGFRonnettBMSeidmanJZainoRJRubinSCEpithelial ovarian cancerBarakatRRMarkmanMRandallMEPrinciples and Practice of Gynecologic OncologyPhiladelphiaWolters Kluwer Health, Lippincott Williams & Wilkins2009763854
   Google Scholar
• OzolsRFBundyBNGreerBEGynecology Oncology GroupPhase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group studyJ Clin Oncol200321173194320012860964
   PubMed Web of Science ®Google Scholar
• MarkmanMRothmanRHakesTSecond-line platinum therapy in patients with ovarian cancer previously treated with cisplatinJ Clin Oncol1991933893931999708
   PubMed Web of Science ®Google Scholar
• EisenhauerEAVermorkenJBvan GlabbekeMPredictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients [see comments]Ann Oncol19978109639689402168
   PubMed Web of Science ®Google Scholar
• MarkmanMMarkmanJWebsterKDuration of response to second-line platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial designJ Clin Oncol200422153120312515284263
   PubMed Web of Science ®Google Scholar
• YapTACardenCPKayeSBBeyond chemotherapy: targeted therapies in ovarian cancerNat Rev Cancer20099316718119238149
   PubMed Web of Science ®Google Scholar
• Fung-Kee-FungMOliverTElitLOzaAHirteHWBrysonPOptimal chemotherapy treatment for women with recurrent ovarian cancerCurr Oncol200714519520817938703
   PubMedGoogle Scholar
• ten Bokkel HuininkWGoreMCarmichaelJTopotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancerJ Clin Oncol1997156218321939196130
   PubMed Web of Science ®Google Scholar
• GordonANFleagleJTGuthrieDParkinDEGoreMELacaveAJRecurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecanJ Clin Oncol200119143312332211454878
   PubMed Web of Science ®Google Scholar
• ParmarMKLedermannJAColomboNet al;ICONAGO CollaboratorsPaclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trialLancet200336193752099210612826431
   PubMed Web of Science ®Google Scholar
• González-MartínAJCalvoEBoverIRandomized phase II trial of carboplatin versus paclitaxel and carboplatin in platinum-sensitive recurrent advanced ovarian carcinoma: a GEICO (Grupo Espanol de Investigacion en Cancer de Ovario) studyAnn Oncol200516574975515817604
   PubMed Web of Science ®Google Scholar
• Pfisterer J, Plante M, Vergote I, et al; AGO-OVAR; NCIC CTG; EORTC GCG. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCGJ Clin Oncol200624294699470716966687
   PubMed Web of Science ®Google Scholar
• BolisGScarfoneGGiardinaGAssociazione per Ricerca in Ginecologia Oncologia (ARGO 96) Study GroupCarboplatin alone vs carboplatin plus epidoxorubicin as second-line therapy for cisplatin- or carboplatin-sensitive ovarian cancerGynecol Oncol20018113911277642
   PubMed Web of Science ®Google Scholar
• CantúMGBudaAParmaGRandomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to firstline platinum-based regimensJ Clin Oncol20022051232123711870165
   PubMed Web of Science ®Google Scholar
• AlbertsDSLiuPYWilczynskiSPSouthwest Oncology GroupRandomized trial of pegylated liposomal doxorubicin (PLD) plus carboplatin versus carboplatin in platinum-sensitive (PS) patients with recurrent epithelial ovarian or peritoneal carcinoma after failure of initial platinum-based chemotherapy (Southwestern Oncology Group Protocol S02000)Gynecol Oncol20081081909417949799
   PubMed Web of Science ®Google Scholar
• MarkmanMMoonJWilczynskiSSingle agent carboplatin versus carboplatin plus pegylated liposomal doxorubicin in recurrent ovarian cancer: final survival results of a SWOG (S0200) phase 3 randomized trialGynecol Oncol2010116332332520044128
   PubMed Web of Science ®Google Scholar
• MonkBJHerzogTJKayeSBTrabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancerJ Clin Oncol201028193107311420516432
   PubMed Web of Science ®Google Scholar
• Pujade-LauraineEWagnerUAavall-LundqvistEPegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapseJ Clin Oncol201028203323332920498395
   PubMed Web of Science ®Google Scholar
• Fung Kee FungMKennedyEFrancisJMackayHmembers of the Gynecologic Cancer Disease Site GroupOptimal Chemotherapy for Recurrent Ovarian CancerToronto, ONProgram in Evidence-based Care (PEBC), Cancer Care Ontario (CCO)2011 Available from: https://www.cancercare.on.ca/common/pages/UserFile.aspx?fileId=34203Accessed December 10, 2012
   Google Scholar
• KatsumataNYasudaMTakahashiFJapanese Gynecologic Oncology GroupDose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trialLancet200937496981331133819767092
   PubMed Web of Science ®Google Scholar
• North Eastern Germany Society of Gynecologic OncologyHycamtin Plus carboplatinum versus established regimens for the treatment of ovarian cancer relapseClinicalTrialsgov [website on the Internet]Bethesda, MDUS National Library of Medicine2011 [updated August 26, 2011]. Available from: http://clinicaltrial.gov/ct2/show/NCT00437307?term=NCT00437307&rank=1NLM identifier: HECTOR. Accessed December 20, 2012
   Google Scholar
• GordonANTondaMSunSRackoffWDoxil Study 30-49 InvestigatorsLong-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancerGynecol Oncol20049511815385103
   PubMed Web of Science ®Google Scholar
• ten Bokkel HuininkWLaneSRRossGAInternational Topotecan Study GroupLong-term survival in a phase III, randomised study of topotecan versus paclitaxel in advanced epithelial ovarian carcinomaAnn Oncol200415110010314679127
   PubMed Web of Science ®Google Scholar
• O’ByrneKJBlissPGrahamJDGerberJVaseyPAKhannaSA phase III study of Doxil/Caelyx versus paclitaxel in platinum-treated, taxane-naive relapsed ovarian cancer [ASCO abstract 808]Proceedings American Society of Clinical Oncology200221203a
   Google Scholar
• GoreMOzaARustinGA randomised trial of oral versus intravenous topotecan in patients with relapsed epithelial ovarian cancerEur J Cancer2002381576311750840
   PubMed Web of Science ®Google Scholar
• MutchDGOrlandoMGossTRandomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancerJ Clin Oncol200725192811281817602086
   PubMed Web of Science ®Google Scholar
• BolisGParazziniFScarfoneGPaclitaxel vs epidoxorubicin plus paclitaxel as second-line therapy for platinum-refractory and -resistant ovarian cancerGynecol Oncol199972160649889031
   PubMed Web of Science ®Google Scholar
• TorriVFlorianiITinazziARandomized trial comparing paclitaxel + doxorubincin (AT) versus paclitaxel (T) as second line therapy for advanced ovarian cancer (AOC) patients in early progression after platinum based chemotherapy [ASCO abstract 1506]Proceedings of the American Society of Clinical Oncology200019381a
   Google Scholar
• BudaAFlorianiIRossiRRandomised controlled trial comparing single agent paclitaxel vs epidoxorubicin plus paclitaxel in patients with advanced ovarian cancer in early progression after platinum-based chemotherapy: an Italian Collaborative Study from the ‘Mario Negri’ Institute, Milan, GONO (Gruppo Oncologico Nord Ovest) group and IOR (Istituto Oncologico Romagnolo) groupBr J Cancer200490112112211715150623
   PubMed Web of Science ®Google Scholar
• SehouliJStengelDOskay-OezcelikGNonplatinum topotecan combinations versus topotecan alone for recurrent ovarian cancer: results of a phase III study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study GroupJ Clin Oncol200826193176318218591555
   PubMed Web of Science ®Google Scholar
• LortholaryALargillierRWeberBGINECO group FranceWeekly paclitaxel as a single agent or in combination with carboplatin or weekly topotecan in patients with resistant ovarian cancer: the CARTAXHY randomized phase II trial from Groupe d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens (GINECO)Ann Oncol201223234635221562072
   PubMed Web of Science ®Google Scholar
• SessaCDe BraudFPerottiATrabectedin for women with ovarian carcinoma after treatment with platinum and taxanes failsJ Clin Oncol20052391867187415774779
   PubMed Web of Science ®Google Scholar
• SmitWMŠufiarskyJSpanikSPhase I/II dose-escalation trial of patupilone every 3 weeks in patients with relapsed/refractory ovarian cancer [ASCO abstract 5056]J Clin Oncol20052316S5056
   Google Scholar
• ColomboNSchwartzPEBamiasAResults of a randomized, open-label, phase 3 trial of patupilone (P) versus pegylated liposomal doxorubicin (PLD) in taxane/platinum refractory/resistant patients with recurrent ovarian, fallopian or peritoneal cancerProceedings of the 35th European Society for Medical Oncology Congress [abstract 4843]October 8–12, 2010Milan, Italy
   Google Scholar
• HirteH WNovel developments in angiogenesis cancer therapyCurr Oncol2009163505419526086
   PubMed Web of Science ®Google Scholar
• BurgerRASillMWMonkBJGreerBESoroskyJIPhase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group StudyJ Clin Oncol200725335165517118024863
   PubMed Web of Science ®Google Scholar
• GarciaAAHirteHFlemingGPhase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortiaJ Clin Oncol2008261768218165643
   PubMed Web of Science ®Google Scholar
• CannistraSAMatulonisUAPensonRTPhase II Study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancerJ Clin Oncol200725335180518618024865
   PubMed Web of Science ®Google Scholar
• Pujade-LauraineEHilpertFWeberBAURELIA: a randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC) [ASCO abstract LBA5002]J Clin Oncol201230S18LBA5002
   Google Scholar
• AghajanianCBlankSVGoffBAOCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancerJ Clin Oncol201230172039204522529265
   PubMed Web of Science ®Google Scholar
• ItamochiHKigawaJClinical trials and future potential of targeted therapy for ovarian cancerInt J Clin Oncol201217543044022926640
   PubMed Web of Science ®Google Scholar
• TewWPColomboNRay-CoquardIVEGF-trap for patients (pts) with recurrent platinum-resistant epithelial ovarian cancer (EOC): preliminary results of a randomized, multicenter phase II study [ASCO abstract 5508]J Clin Oncol200725S185508
   Google Scholar
• GotliebWHAmantFAdvaniSIntravenous afibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled studyLancet Oncol201213215416222192729
   PubMed Web of Science ®Google Scholar
• HirteHWVidalLFlemingGFA phase II study of cediranib (AZD2171) in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: final results of PMH, Chicago and California consortia Trial [ASCO abstract 5521]J Clin Oncol2008265521
   Web of Science ®Google Scholar
• MatulonisUABerlinSIvyPCediranib, an oral inhibitor of vascularendothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancerJ Clin Oncol200927335601560619826113
   PubMed Web of Science ®Google Scholar
• Boehringer Ingelheim Pharmaceuticals A randomized placebo-controlled Phase 2 study of continuous maintenance treatment with BIBF1120 following chemotherapy in patients with relapsed ovarian cancerClinicalTrialsgov [website on the Internet]Bethesda, MDUS National Library of Medicine2011 [updated August 26, 2011]. Available from: http://clinicaltrial.gov/ct2/show/NCT00710762?term=NCT00710762&rank=1NLM identifier: NCT00710762. Accessed December 20, 2012
   Google Scholar
• LedermannJAHackshawAKayeSRandomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF1120 after chemotherapy for relapsed ovarian cancerJ Clin Oncol201129283798380421859991
   PubMed Web of Science ®Google Scholar
• MateiDSillMWDeGeestKBristowREPhase II trial of sorafenib in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer; a Gynaecologic Oncology Group Study [ASCO abstract 5537]J Clin Oncol200826553718809605
   PubMed Web of Science ®Google Scholar
• AzadNSPosadasEMKwitkowskiVECombination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activityJ Clin Oncol200826223709371418669456
   PubMed Web of Science ®Google Scholar
• WelchSHirteHElitLCA-125 response as a marker of clinical benefit in patients with recurrent ovarian cancer treated with gemcit-abine and sorafenib: A trial of the PMH Phase II Consortium [ASCO abstract 5519]J Clin Oncol200725Suppl 18S551918048829
   PubMed Web of Science ®Google Scholar
• Charite University, Berlin, GermanyEfficacy and safety study of sorafenib with Topotecan in patients with platinum resistant recurrent ovarian cancerClinicalTrialsgov [website on the Internet]Bethesda, MDUS National Library of Medicine2011 [updated August 26, 2011]. Available from: http://clinicaltrial.gov/ct2/show/NCT01047891?term=NCT01047891&rank=1NLM identifier: NCT 01047891. Accessed December 20, 2012
   Google Scholar
• NCISorafenib with or without paclitaxel and carboplatin in treating patients with recurrent ovarian cancer, primary peritoneal cancer or fallopian tube cancerClinicalTrialsgov [website on the Internet]Bethesda, MDUS National Library of Medicine2011 [updated August 26, 2011]. Available from: http://clinicaltrials.gov/ct2/show/NCT00096200?term=NCT00096200&rank=1NLM identifier: NCT00096200. Accessed December 20, 2012
   Google Scholar
• BiagiJJOzaAMChalchalHIA phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group StudyAnn Oncol201122233534020705911
   PubMed Web of Science ®Google Scholar
• BaumannKHdu BoisAMeierWA phase II trial (AGO 2.11) in platinum-resistant ovarian cancer: a randomized multicenter trial with sunitinib (SU11248) to evaluate dosage, schedule, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor monotherapyAnn Oncol20122392265227122377563
   PubMed Web of Science ®Google Scholar
• CamposSMPensonRTMatulonisUA phase II trial of Sunitinib malate in recurrent and refractory ovarian, fallopian tube and peritoneal carcinomaGynecol Oncol892012 Pii: S0090-8258(12)00652-X
   Web of Science ®Google Scholar
• FriedlanderMHancockKCRischinDA Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancerGynecol Oncol20101191323720584542
   PubMed Web of Science ®Google Scholar
• OakninAGonzalez-MartinAGarcíaYA phase II study of pazopanib in recurrent or persistent ovarian (EOC), peritoneal (PPC), or fallopian tube cancer (FTC): a Spanish Ovarian Cancer Group (GEICO) study [ASCO abstract 5068]J Clin Oncol2012305068
   Web of Science ®Google Scholar
• BuckanovichRJBergerRSellaAActivity of cabozantinib (XL184) in advanced ovarian cancer patients (pts): results from a phase II randomized discontinuation trial (RDT) [ASCO abstract 5008]J Clin Oncol2011295008
   Web of Science ®Google Scholar
• KarlanBYOzaAMRichardsonGERandomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancerJ Clin Oncol201230436237122184370
   PubMed Web of Science ®Google Scholar
• AMGENTRINOVA-1 A study of AMG386 or placebo in combination with weekly paclitaxel chemotherapy as treatment for ovarian cancer, primary peritoneal cancer and fallopian tube cancerBethesda, MDUS National Library of Medicine2011 [updated August 26, 2011]. Available from: http://clinicaltrial.gov/ct2/show/NCT01204749?term=TRINOVA-1&rank=1NLM identifier:TRINOVA-1. Accessed December 20, 2012
   Google Scholar
• AMGENTRINOVA-2 TRial IN OVArian cancerBethesda, MDUS National Library of Medicine2011 [updated August 26, 2011]. Available from: http://clinicaltrial.gov/ct2/show/NCT01281254?term=TRINOVA-2&rank=1NLM identifier: TRINOVA-2. Accessed December 20, 2012
   Google Scholar
• SiwakDRCareyMHennessyBTTargeting the epidermal growth factor receptor in epithelial ovarian cancer: current knowledge and future challengesJ Oncol2010201056893820037743
   PubMedGoogle Scholar
• ZeineldinRMullerCYStackMSHudsonLGTargeting the EGF receptor for ovarian cancer therapyJ Oncol2010414676
   Google Scholar
• ShengQLiuJThe therapeutic potential of targeting the EGFR family in epithelial ovarian cancerBr J Cancer201110481241125421364581
   PubMed Web of Science ®Google Scholar
• PosadasEMKwitkowskiVKotzHLA prospective analysis of imatinib-induced c-KIT modulation in ovarian cancer: a phase II clinical study with proteomic profilingCancer2007110230931717559139
   PubMed Web of Science ®Google Scholar
• JelovacDArmstrongDKRole of farletuzumab in epithelial ovarian carcinomaCurr Pharm Des201218253812381522591419
   PubMed Web of Science ®Google Scholar
• MorphotekAn efficacy and safety study of MORAb-003 in platinum-resistant or refractory relapsed ovarian cancerBethesda, MDUS National Library of Medicine2011 [updated August 26, 2011]. Available from: http://clinicaltrial.gov/ct2/show/NCT00738699?term=MORAB+in+platinum+resistent+ovarian+cancer&rank=1NLMidentifier: FAR-122. Accessed December 20, 2012
   Google Scholar
• NaumannRWSymanowskiJTGhamandeSAPRECEDENT: a randomized phase II trial comparing EC145 and pegylated liposomal doxorubicin (PLD) in combination, versus PLD alone, in subjects with platinum-resistant ovarian cancer [ASCO abstract LBA5012b]J Clin Oncol201028S18LBA5012b
   Google Scholar
• ENDOCYTEStudy for women with platinum resistant ovarian cancer evaluating EC145 in combination with Doxil^®Bethesda, MDUS National Library of Medicine2011 [updated August 26, 2011]. Available from: http://clinicaltrial.gov/ct2/show/NCT01170650?term=NCT01170650&rank=1NLM identifier: NCT01170650. Accessed December 20, 2012
   Google Scholar
• DantzerFde La RubiaGMénissier-De MurciaJHostomskyZde MurciaGSchreiberVBase excision repair is impaired in mammalian cells lacking Poly(ADP-ribose) polymerase-1Biochemistry200029257559756910858306
   PubMed Web of Science ®Google Scholar
• AudehMWPensonRTFriedlanderMPhase II trial of the oral PARP inhibitor olaparib (AZD2281) in BRCA-deficient advanced ovarian cancer [ASCO abstract 5500]J Clin Oncol200927S155500
   Google Scholar
• KayeSBKaufmanBLubinskiJPhase II open label, randomized, multicentre study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor to pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancerJ Clin Oncol201230437237922203755
   PubMed Web of Science ®Google Scholar
• LedermannJAHarterPGourleyCPhase II randomized placebo-controlled study of olaparib (AZD2281) in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC) [ASCO abstract 5003]J Clin Oncol201129S5003
   Web of Science ®Google Scholar
• GelmonKATischkowitzMMackayHOlaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2 multicentre, open-label, non-randomised studyLancet Oncol201112985286121862407
   PubMed Web of Science ®Google Scholar
• AbbottA trial of ABT-888 in combination with Temozolomide versus pegylated liposomal doxorubicin alone in ovarian cancerBethesda, MDUS National Library of Medicine2011 [updated August 26, 2011]. Available from: http://clinicaltrials.gov/ct2/show/NCT01113957?term=NCT01113957&rank=1NLM identifier: NCT01170650. Accessed December 20, 2012
   Google Scholar